Gotham Asset Management LLC Purchases Shares of 24,299 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Gotham Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 24,299 shares of the company's stock, valued at approximately $775,000.

A number of other institutional investors and hedge funds have also made changes to their positions in APLS. Avoro Capital Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 10.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock worth $390,011,000 after purchasing an additional 1,111,111 shares during the period. Vanguard Group Inc. lifted its position in Apellis Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company's stock worth $320,569,000 after buying an additional 230,450 shares during the last quarter. Jennison Associates LLC boosted its stake in Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company's stock worth $88,084,000 after buying an additional 939,289 shares during the period. AQR Capital Management LLC boosted its stake in Apellis Pharmaceuticals by 127.2% during the fourth quarter. AQR Capital Management LLC now owns 1,856,442 shares of the company's stock worth $59,239,000 after buying an additional 1,039,182 shares during the period. Finally, Geode Capital Management LLC increased its position in Apellis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company's stock valued at $58,699,000 after acquiring an additional 28,426 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Stock Up 2.1%

Shares of APLS stock traded up $0.36 on Thursday, hitting $17.78. The stock had a trading volume of 1,690,921 shares, compared to its average volume of 2,261,638. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $43.99. The business has a 50 day moving average price of $19.91 and a 200 day moving average price of $26.50. The company has a market cap of $2.23 billion, a PE ratio of -8.76 and a beta of 0.73. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. During the same quarter in the prior year, the firm posted ($0.54) EPS. The company's revenue for the quarter was down 3.2% compared to the same quarter last year. Research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on APLS. Royal Bank of Canada lowered their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a report on Thursday, May 8th. Wells Fargo & Company reduced their price objective on shares of Apellis Pharmaceuticals from $30.00 to $26.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Citigroup decreased their price objective on shares of Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating for the company in a research note on Thursday. The Goldman Sachs Group cut their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, Bank of America downgraded Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $41.00 to $23.00 in a report on Friday, May 9th. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $39.89.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.50% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).